These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 18460519)

  • 1. Targeting growth factors in lung cancer.
    Hodkinson PS; Mackinnon A; Sethi T
    Chest; 2008 May; 133(5):1209-16. PubMed ID: 18460519
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting mTOR signaling in lung cancer.
    Marinov M; Fischer B; Arcaro A
    Crit Rev Oncol Hematol; 2007 Aug; 63(2):172-82. PubMed ID: 17540577
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeted therapies for non-small cell lung cancer.
    Dempke WC; Suto T; Reck M
    Lung Cancer; 2010 Mar; 67(3):257-74. PubMed ID: 19914732
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting the MET gene for the treatment of non-small-cell lung cancer.
    Gelsomino F; Facchinetti F; Haspinger ER; Garassino MC; Trusolino L; De Braud F; Tiseo M
    Crit Rev Oncol Hematol; 2014 Feb; 89(2):284-99. PubMed ID: 24355409
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeted therapy in non-small-cell lung cancer.
    Herbst RS
    Oncology (Williston Park); 2002 Sep; 16(9 Suppl 9):19-24. PubMed ID: 12375797
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The role of anti-epidermal growth factor receptor and anti-vascular endothelial growth factor therapies in the treatment of non-small-cell lung cancer.
    Langer C; Soria JC
    Clin Lung Cancer; 2010 Mar; 11(2):82-90. PubMed ID: 20199973
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fibroblast growth factor signaling in non-small-cell lung cancer.
    Semrad TJ; Mack PC
    Clin Lung Cancer; 2012 Mar; 13(2):90-5. PubMed ID: 21959109
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multitargeted anti-angiogenic agents and NSCLC: clinical update and future directions.
    Ellis PM; Al-Saleh K
    Crit Rev Oncol Hematol; 2012 Oct; 84(1):47-58. PubMed ID: 22405734
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting brain metastases in ALK-rearranged non-small-cell lung cancer.
    Zhang I; Zaorsky NG; Palmer JD; Mehra R; Lu B
    Lancet Oncol; 2015 Oct; 16(13):e510-21. PubMed ID: 26433824
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preclinical strategies targeted at non-small-cell lung cancer signalling pathways with striking translational fallout.
    Favoni RE; Alama A
    Drug Discov Today; 2013 Jan; 18(1-2):11-24. PubMed ID: 22885521
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Roles of Hippo signaling in lung cancer.
    Wang Y; Ding W; Chen C; Niu Z; Pan M; Zhang H
    Indian J Cancer; 2015 Nov; 52 Suppl 1():e1-5. PubMed ID: 26548931
    [TBL] [Abstract][Full Text] [Related]  

  • 12. FGFR Signaling as a Target for Lung Cancer Therapy.
    Desai A; Adjei AA
    J Thorac Oncol; 2016 Jan; 11(1):9-20. PubMed ID: 26762735
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New molecular targeted therapies integrated with radiation therapy in lung cancer.
    Provencio M; Sánchez A; Garrido P; Valcárcel F
    Clin Lung Cancer; 2010 Mar; 11(2):91-7. PubMed ID: 20199974
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Emerging role of epidermal growth factor receptor inhibition in therapy for advanced malignancy: focus on NSCLC.
    Langer CJ
    Int J Radiat Oncol Biol Phys; 2004 Mar; 58(3):991-1002. PubMed ID: 14967461
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New targeted therapies for non-small-cell lung cancer: a focus on the epidermal growth factor receptor.
    Crawford J
    J Natl Compr Canc Netw; 2003 Jan; 1 Suppl 1():S78-86. PubMed ID: 19795580
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mesothelioma and small cell lung cancer.
    Tsao AS; Heymach J
    J Thorac Oncol; 2011 Nov; 6(11 Suppl 4):S1825-6. PubMed ID: 22005546
    [No Abstract]   [Full Text] [Related]  

  • 17. Growth factors mediated cell signalling in prostate cancer progression: Implications in discovery of anti-prostate cancer agents.
    Joshi G; Singh PK; Negi A; Rana A; Singh S; Kumar R
    Chem Biol Interact; 2015 Oct; 240():120-33. PubMed ID: 26297992
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting angiogenesis in lung cancer.
    Sandler AB
    Semin Oncol; 2005 Dec; 32(6 Suppl 10):S16-22. PubMed ID: 16459175
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel FGFR inhibitor ponatinib suppresses the growth of non-small cell lung cancer cells overexpressing FGFR1.
    Ren M; Hong M; Liu G; Wang H; Patel V; Biddinger P; Silva J; Cowell J; Hao Z
    Oncol Rep; 2013 Jun; 29(6):2181-90. PubMed ID: 23563700
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular determinants of radiation response in non-small cell lung cancer.
    Yom SS; Diehn M; Raben D
    Semin Radiat Oncol; 2015 Apr; 25(2):67-77. PubMed ID: 25771410
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.